Start Date
April 2, 2024
Primary Completion Date
April 30, 2026
Study Completion Date
November 30, 2026
HMPL-523
Syk inhibitor
Sykehuset Ostfold Kalnes (fosta) / Osfold Hospital Trust (MSL), Grålum
Charite university, Berlin
Georgetown University Medical Center - Georgetown Lombardi Comprehensive Cancer Center, Georgetown
Center for Cancer and Blood Disorders, Bethesda
East Carolina University, Brody School of Medicine, Greenville
Hospital Gregorio Maranon Madrid, Madrid
Clinica Universidad de Navarra, Madrid
Hospital Infanta Leonor, Madrid
Fundacion Jimenez Diaz, Madrid
Hospital Morales Meseguer, Murcia
Marien Hospital Dusseldorf, Düsseldorf
Taussig Cancer Institute, Cleveland
Oklahoma Cancer Specialists and Research Institute, Tulsa
Texas Oncology San Antonio Medical Center, San Antonio
San Juan Oncology Associates, Farmington
Childrens Hospital of California, Irvine
University of Washington (UW) Medical Center, Seattle
Massachusetts General Hospital, Boston
Peninsula Private Hospital, Frankston
The Perth Blood Institute (PBI) Hollywood Specialist Centre, West Perth
Royal Adelaide Hospital, Adelaide
Canberra Hospital, Canberra
UMG Gottingen Hämatologie, Göttingen
University Hospital of Schleswig-Holstein, Department of Haematology and Oncology, Lübeck
Oslo University Hospital, Oslo
Hospital Universitari Vall d'Hebron, Barcelona
Hospital del Mar Barcelona, Barcelona
University de Burgos, Burgos
Lead Sponsor
Hutchmed
INDUSTRY